Movement Alert｜WUXI BIO Rises 3.19% in Regular Trading, CXO Sector Rallies on Strong Peer Earnings and Upcoming Interim Results

Market Focus

Aug 07

On August 7, WUXI BIO rose 3.19% in regular trading, trading at HKD 42.6/share, with turnover of HKD 233 million.

On the news front, the CXO sector continues to strengthen broadly following WuXi AppTec's robust interim results disclosure. WuXi AppTec reported H1 revenue of RMB 28.897 billion, up 38.93% year-over-year, with non-GAAP net profit surging 89.39% YoY, lifting the entire pharmaceutical outsourcing sector. On the same day, Pharmaron rose 5.30%, WuXi AppTec gained 3.17%, and WuXi XDC added 2.80%, reflecting a broad-based rally across CXO names.

Additionally, WUXI BIO's board is scheduled to review its interim results on August 25, with the market maintaining positive expectations. Institutional research indicates that the CXO upcycle has entered a profit realization phase, supported by global innovative drug primary market financing surging 58.5% YoY in H1, underpinning continued sector valuation recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1173134117"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173134117\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173134117?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 09:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173134117","market":"us","top_or_hot":-1,"title":"Movement Alert｜WUXI BIO Rises 3.19% in Regular Trading, CXO Sector Rallies on Strong Peer Earnings and Upcoming Interim Results","media":"Market Focus","content":"<p><p>On August 7, WUXI BIO rose 3.19% in regular trading, trading at HKD 42.6/share, with turnover of HKD 233 million.</p><p>On the news front, the CXO sector continues to strengthen broadly following WuXi AppTec's robust interim results disclosure. WuXi AppTec reported H1 revenue of RMB 28.897 billion, up 38.93% year-over-year, with non-GAAP net profit surging 89.39% YoY, lifting the entire pharmaceutical outsourcing sector. On the same day, Pharmaron rose 5.30%, WuXi AppTec gained 3.17%, and WuXi XDC added 2.80%, reflecting a broad-based rally across CXO names.</p><p>Additionally, WUXI BIO's board is scheduled to review its interim results on August 25, with the market maintaining positive expectations. Institutional research indicates that the CXO upcycle has entered a profit realization phase, supported by global innovative drug primary market financing surging 58.5% YoY in H1, underpinning continued sector valuation recovery.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WUXI BIO Rises 3.19% in Regular Trading, CXO Sector Rallies on Strong Peer Earnings and Upcoming Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WUXI BIO Rises 3.19% in Regular Trading, CXO Sector Rallies on Strong Peer Earnings and Upcoming Interim Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 09:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, WUXI BIO rose 3.19% in regular trading, trading at HKD 42.6/share, with turnover of HKD 233 million.</p><p>On the news front, the CXO sector continues to strengthen broadly following WuXi AppTec's robust interim results disclosure. WuXi AppTec reported H1 revenue of RMB 28.897 billion, up 38.93% year-over-year, with non-GAAP net profit surging 89.39% YoY, lifting the entire pharmaceutical outsourcing sector. On the same day, Pharmaron rose 5.30%, WuXi AppTec gained 3.17%, and WuXi XDC added 2.80%, reflecting a broad-based rally across CXO names.</p><p>Additionally, WUXI BIO's board is scheduled to review its interim results on August 25, with the market maintaining positive expectations. Institutional research indicates that the CXO upcycle has entered a profit realization phase, supported by global innovative drug primary market financing surging 58.5% YoY in H1, underpinning continued sector valuation recovery.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1173134117","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173134117","pubTimestamp":1786067116,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, WUXI BIO rose 3.19% in regular trading, trading at HKD 42.6/share, with turnover of HKD 233 million.On the news front, the CXO sector continues to strengthen broadly following WuXi...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"走势提醒|药明生物常规交易上涨 3.19%，CXO 板块因强劲的同业盈利和即将公布的中期业绩而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On August 7, WUXI BIO rose 3.19% in regular trading, trading at HKD 42.6/share, with turnover of HKD 233 million.On the news front, the CXO sector continues to strengthen broadly following WuXi AppTec's robust interim results disclosure. WuXi AppTec reported H1 revenue of RMB 28.897 billion, up 38.93% year-over-year, with non-GAAP net profit surging 89.39% YoY, lifting the entire pharmaceutical outsourcing sector. On the same day, Pharmaron rose 5.30%, WuXi AppTec gained 3.17%, and WuXi XDC added 2.80%, reflecting a broad-based rally across CXO names.Additionally, WUXI BIO's board is scheduled to review its interim results on August 25, with the market maintaining positive expectations. Institutional research indicates that the CXO upcycle has entered a profit realization phase, supported by global innovative drug primary market financing surging 58.5% YoY in H1, underpinning continued sector valuation recovery.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}